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The transformation of chronic lymphocytic leukemia (CLL) to large cell lymphoma (Richter's syndrome) is well described. However, there have been recent reports of Hodgkin's type Richter's syndrome (H-RS) in patients with CLL. [1] [2] [3] In this report we describe three additional cases of H-RS transforming from CLL in patients who had been treated for varying periods of time.
A summary of patients' clinical features and outcomes is presented in Table 1 . The patients were aged 58-70 years and had been treated for CLL with varying chemotherapy combinations with the onset of H-RS occurring 38-132 months after the diagnosis of CLL.
Biopsies which demonstrated H-RS were carried out in all three patients because of clinically progressive disease. Patient GC presented with a retroperitoneal mass and significant weight loss 11 years after the initial diagnosis of CLL; the retroperitoneal mass was biopsied. Thirty-eight months after initial presentation as CLL, patient GM developed immune thrombocytopenia which was refractory to steroids and high-dose gamma globulin; he underwent splenectomy and splenic hilar node biopsy. Patient KB had fever and night sweats in association with progressively increasing generalized lymphadenopathy 10 years after initial presentation of CLL. On CT scanning she also had hepatic and splenic lesions. Fine needle aspiration of the liver lesion and a bone marrow biopsy were carried out.
The histopathology was reviewed independently by two pathologists (SJ and DE). The diagnosis of H-RS was made on lymph node biopsy in two patients (GM and GC) and on bone marrow biopsy in one patient (KB).
In two patients (GM and GC) with lymph node biopsies, the nodes were 11-22 mm in diameter. There was a diffuse replacement of the lymph node architecture with sheets of small lymphocytes with rounded nuclei and clumped chromatin and scant cytoplasm. There was focal sclerosis. Scattered within this were single cells and clusters of large cells with irregular nuclei, pale vesicular chromatin and large eosinophilic nucleoli; some of the larger cells had abundant amphophilic cytoplasm (Hodgkin's cells Figure 1 ). In the third patient (KB) in whom the diagnosis was based on bone marrow biopsy, there was an admixture of histiocytes and fibroblasts among the Hodgkin's cells; fine needle aspiration of the liver lesion revealed a polymorphic cellular infiltrate including Hodgkin's cells. On immunohistology, the large Hodgkin's cells were CD15 + , CD30
+ and EMA − in all three cases. In case 1 (GC) the background small lymphocytes stained with CD20; in case 2, the larger cells showed positive staining with CD20 but not CD79a; most of the background lymphocytes were CD20-positive, but there were scattered cells which were positive for CD3 and UCHL1. In case 3 (KB) the background cells were positive with CD68 (histiocytes) and CD3 (T cells). 
Figure 1
Scattered within the background of small lymphocytes there are typical uninucleate and multinucleate Hodgkin's cells (×400).
Large cell transformation (Richter's syndrome) occurs in about 3-10% cases of CLL and it has been recently shown that this represents clonal evolution of the underlying B cell neoplasm. 4 In the last 8 years however, cases of Richter's syndrome with Hodgkin's-like cells (H-RS) supervening on CLL have been described. [1] [2] [3] The comparative incidence of the two types of transformation is difficult to determine. In a study involving 1374 cases of CLL at the MD Anderson Hospital (Houston, TX, USA) there were 47 cases of large cell type Richter's syndrome compared to only seven cases of Hodgkin's type of transformation. 3 However, this may be an underestimate since biopsies of lymph nodes or other extranodal sites are not routinely carried out in many patients when the disease is progressing because the features are attributed to progressive CLL.
In an analysis of second cancers in patients with CLL, an almost eight-fold risk of Hodgkin's disease has been demonstrated. 5 Indeed, this is higher than the risk for any other malignancy in CLL and may represent a clonal evolution rather than a second separate malignancy.
In all three of our cases the diagnosis of H-RS was made when the biopsies were carried out for clinically progressive disease. Our cases were classified histologically as mixed cellularity subtype with the limitation that in the third case the subtyping was based upon bone marrow rather than lymph node biospy. Among the published cases, a majority were mixed cellularity type (57%), followed by nodular sclerosing (30%), nodular lymphocyte predominant type (9%) and lymphocyte-depleted type (4%). Furthermore, Weisenberg et al 2 have reported two cases of nodular lymphocyte predominant type of H-RS. The immunophenotypic features of our cases were typical of Hodgkin's disease and these were associated with the appropriate background. The Hodgkin's cells in all three of our cases were CD15(+), CD30(+) and EMA(−).
It has been suggested that there are two types of H-RS: type-1 in which the Hodgkin's cells are scattered in a background of CLL cells (like our first two cases) and type-2, in which the Hodgkin's cells are present in a typical polymorphic background (like our third case). Recently, it has been demon- Chl, chlorambucil; P, prednisolone; C, cyclophosphamide; V, vincristine; MOPP, nitrogen mustard, oncovin, procarbazine and prednisolone; ABVD, adriamycin, bleomycin, vinblastine, dacarbazine; T-teniposide; CVPP, cyclophosphamide, vinblastine, procarbazine prednisolone; EVAD, etoposide, vinblastine, adriamycin, dexamethasone; CDE, cyclophosphamide, dexamethasone, etoposide.
strated that mature B cells can transform into cells with the morphology and the immunophenotype of H-RS cells. 6 In view of these findings, the above two subtypes of H-RS may represent the same entity. It is possible that H-RS in CLL may result from genetic alterations that result in the morphologic and immunophenotypic features, cytokine production profile and stromal reactions that manifest as HD. 6 An association with Epstein-Barr virus infection has been described in these cases. 7 This was not tested in our patients. Two of our patients died at 4 months and 6 months after the diagnosis of H-RS but the third patient is alive 48 months after the development of H-RS. The median survival of such patients in the previous series has been reported to be 13 months. [1] [2] [3] We conclude that in addition to the well recognised large cell transformation, development of rarer type of H-RS needs to be considered in CLL patients with progressive disease. The authors fail to discuss their findings in relation to the results of the available comprehensive studies on the subject. [2] [3] [4] The study of Wagner et al, 5 cited by the authors, was the first analysis of V genes in MM; however, it was confounded by the inclusion of only seven MM cases among a large group of other B cell lymphoproliferative disorders, three of which were carrying out-of-frame V genes presumably derived from -expressing MM (since PCR was applied on genomic DNA); therefore, V /J gene usage, hypermutation and N-region diversity could not be reliably discerned as a result of the small number of -expressing MM. 5 We and others [2] [3] [4] first demonstrated that the expressed clonogenic V and V genes in MM, similar to V H genes, are usually hypermutated indicating the presumed nature of their precursor, ontogenetically assigned to post-germinal center (GC) memory B cell, that has undergone antigen selection.
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N-nucleotide insertions in V -J junctions, reflecting the activity of TdT at the time of -light chain (LC) gene assembly
